跳至主要内容
临床试验/NCT01077609
NCT01077609已完成不适用

Fluticasone Propionate Nasal Spray (Flixonase) Safety in Patients With Allergic Rhinitis Registered in the UK General Practice Research Database

GlaxoSmithKline0 个研究点目标入组 1 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1
主要终点
Steroid-related outcomes: Cataracts, Glaucoma, Nasal septum perforation, Hypercorticism, Adrenal insufficiency, Fractures (limited to hip, wrist and vertebral as proxies for osteoporosis), Otitis media, Sinusitis, Infectious complications of sinusitis

研究概览

简要总结

This is an inception cohort study that analyses data from an administrative medical records database. The two inception cohorts are: 1) patients initiated on intranasal FP and 2) patients initiated on another INS (not FP). The candidates for the inception cohorts did not use any intranasal steroid in the year prior to initiation.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
4 Years 至 85 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient records dated between January 1990 - January 2002 were used to develop the overall study cohort. The cohort was composed of the following patients:
  • All patients with at least one prescription for Flixonase
  • A random sample of patients having at least one prescription for an INS other than Flixonase

排除标准

  • Patient-level exclusion
  • Patients with less than 180 days of continuous eligibility before index date
  • Patients who are under four years of age at index date
  • Patients who are older than 85 years of age at index date
  • Episode-level exclusion
  • When patient history was divided into Flixonase or other INS use episodes, patients with less than 120 days of eligibility after the last prescription in the episode Patients with an event of interest 180 days prior to patients' entry into the cohort or anytime prior to an episode index date were automatically excluded from the analysis of that event. This exclusion criterion was applied to rule out prevalent conditions.

研究组 & 干预措施

Allergic rhinitis (AR) & Flixonase

Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate

干预措施: Intermittent, sub-chronic and chronic Flixonase use (Drug)

AR & prescription for intranasal steroid other than Flixonase

Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase

干预措施: Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase (Drug)

结局指标

主要结局

Steroid-related outcomes: Cataracts, Glaucoma, Nasal septum perforation, Hypercorticism, Adrenal insufficiency, Fractures (limited to hip, wrist and vertebral as proxies for osteoporosis), Otitis media, Sinusitis, Infectious complications of sinusitis

时间窗: Exposure episodes are defined as any series of prescriptions filled within 60 days of one another. Observation periods capture incident events beginning with the first prescription in the episode and ending 120 days after the last fill date.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Flixonase Safety in Patients With Allergic Rhinitis... | 临床试验